YVR Aesthetic Training & Study Centre has completed a number of clinical studies in partnership with industry. The research has deepened our understanding of the science and evidence behind the treatments, protocols and devices allowing our team to bring a high level of expertise to our training.
The team at YVR Aesthetic Training & Study Centre continues to work with leading pharmaceutical companies to help bring the latest in innovation and advances to the medical aesthetic field. If you are interested in participating in one of the current clinical trials, please contact us with the subject line: Clinical Studies Participant in your message.
NCTF® BOOST 135 HA is a unique anti-aging, poly-revitalizing complex that nourishes the skin by providing the ingredients that it needs to thrive. This study aims to establish the in clinic application technique for cosmetic topical use only and not for injection.
To evaluate the safety and effectiveness of the Allergan CoolSculpting® system using CoolAdvantage applicators for non-invasive subcutaneous fat reduction of the upper arms and inner thighs in participants of Chinese descent. (ClinicalTrials.gov Identifier: NCT04142450)
This study aims to develop a measurement scale for Masseters
This study aims to generate data that conveys participant's experiences such as their overall satisfaction with the CoolSculpting® treatment for their belly and love handles. By doing this, the study will provide insights for doctors to better inform participants about the expected outcomes. (ClinicalTrials.gov Identifier: NCT0390910)
Dr. Braun and his team brought another amazing study to light – the Xeomin™ Calf Study. The study examined the fascinating effects of neuromodulators such as Xeomin™ on the calves to measure slimming.
With over 5 years of experience with Botulinum Toxin injections, Dr. Braun published a paper to summarize his findings. His publication was intended for his peers to examine various factors that appear to result in satisfied patients with a high retention rate. He established that a panfacial treatment of botulinum toxin injected in multiple sites and with the appropriate dosing improves patient retention and thus changed the “face of Botox®”.